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1,3-Dimethylamylamine (DMAA) is offered for sale on the Internet as an active ingredient of 
so-called “pre-workout products” and weight loss products. The Federal Institute for Risk 
Assessment (BfR) has scientifically assessed these products which appear to be taken by 
athletes in particular. 
 
Depending on the administered dose, DMAA can lead to an acute temporary increase in 
blood pressure in humans. There are now early provisional indications that continued use 
may, in combination with caffeine, lead to a chronic increase in blood pressure. A 
pronounced rise in blood pressure may increase cardiac work to such a degree that 
undesirable cardiovascular effects are precipitated which range from shortness of breath to 
tightening of the chest or a possible myocardial infarction. In addition, a significant acute 
increase in blood pressure can increase the risk of cerebral haemorrhage. This notably 
applies to persons with increased individual risks such as cerebral aneurysms (local dilation 
of blood vessels in the brain). The extent of possible health risks is influenced by the DMAA 
dose administered and the blood pressure of the individual concerned. In addition, other 
individual factors such as risk factors for coronary heart disease can influence the health 
risk1.  
 
According to its own statements, the US-American Food and Drug Administration (FDA) has 
received 42 adverse event reports in connection with the use of DMMA-containing products. 
Some reports include cardiac disorders, nervous system disorders, psychiatric disorders and 
death. Details on the reports, for example regarding the ingested quantities of DMAA, the 
type of adverse events observed, the closer circumstances of the incidents, and the question 
whether other substances were taken concomitantly, are not available. According to the 
statement of the FDA, the reports did not establish that DMAA was the cause of the adverse 
incidents. With its communication released on 27 April 2012, the FDA has classified DMAA-
containing products which are marketed by various manufacturers in the USA as non-
compliant with the law for formal reasons. The BfR does not know whether such products 
continue to be sold in Germany. 
 
The current state of knowledge on the health effects of DMAA oral intake in humans is full of 
gaps. Even based on current knowledge, persons with increased blood pressure and those 
suffering from other cardiovascular diseases should refrain from taking DMAA-containing 
products. Some providers specifically mention this risk group.  
 
The BfR recommends investigating whether the formal requirements for the sale of DMAA 
products as food are met in Germany, in particular whether DMAA is to be classified as novel 
food or novel food ingredient. Classification of DMAA as a pharmaceutical product too should 
be considered. If DMAA containing products can be sold as food, it is to be established 
whether or not they are to be classified as “unsafe foods”.  
 
                                                
1 Coronary heart disease is a narrowing of the coronary vessels which supply the heart 
muscle with blood. Typical risk factors include nicotine use and an increased LDL cholesterol 
level. 
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The full version of this BfR Opinion is available in German on 
http://www.bfr.bund.de/cm/343/gesundheitliche-bewertung-von-dmaa-als-inhaltsstoff-von-
produkten-die-als-lebensmittel-in-verkehr-gebracht-werden.pdf 
 
 
 
